In a significant shift in American drug policy, the United States has moved to ease restrictions on cannabis for medical use, a decision expected to widen patient access, expand scientific research and alter the regulatory landscape around marijuana. The development comes as the US Department of Justice announced that FDA-approved marijuana products and cannabis regulated under state medical marijuana programmes would be placed under Schedule III of the Controlled Substances Act, a major departure from their long-held Schedule I classification.
The move is being viewed as one of the most consequential federal changes to cannabis policy in decades. Until now, marijuana had been grouped with drugs considered to have no accepted medical use and a high potential for abuse. Its shift to Schedule III places it in a category that recognises medicinal value while keeping federal controls intact.
Officials said the decision is intended to support both immediate and long-term reforms. For patients, it could ease access to medical cannabis products in states where such programmes already exist. For researchers, it could reduce bureaucratic hurdles that have long hampered studies into cannabis use for chronic pain, neurological disorders and other medical conditions.
For years, researchers argued that Schedule I restrictions made cannabis studies unusually difficult, requiring multiple layers of approval and limiting access to research-grade products. The revised classification is expected to simplify that process and encourage broader scientific inquiry into therapeutic uses as well as risks associated with cannabis consumption.
The order also carries implications for the cannabis industry. Analysts say rescheduling could provide tax relief to licensed medical cannabis businesses, which had been burdened under federal tax provisions applied to Schedule I substances. It may also improve prospects for funding and investment in the medical cannabis sector, though experts caution that broader banking and legal barriers remain unresolved.
While the move has been welcomed by reform advocates, it does not amount to nationwide legalisation of marijuana, nor does it immediately change the legal status of recreational cannabis at the federal level. Officials have stressed that federal restrictions against illicit trafficking remain in place.
The Justice Department has also initiated an expedited administrative hearing process beginning in June to consider broader changes to marijuana’s federal classification. That process could determine whether wider rescheduling measures follow, potentially shaping the next phase of cannabis reform in the US.
Supporters say the decision reflects the growing disconnect between federal law and state-level policies, with dozens of states already permitting medical marijuana use. They argue the shift acknowledges the reality of widespread medical use while establishing stronger regulatory oversight.
Critics, however, have raised concerns over possible public health consequences, warning that loosening restrictions could increase misuse or complicate enforcement. Some experts have also cautioned that while the policy opens doors for research and access, its practical impact may depend on how federal agencies implement the change.
Still, the policy shift is being seen as a landmark step in mainstreaming medical cannabis within the American healthcare and regulatory system. With research opportunities likely to grow and future hearings set to examine broader reforms, the decision could prove a turning point in the long-running debate over marijuana policy in the United States.
